youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
HALO:NASDAQ
Halozyme Therapeutics, Inc.
$131.18
arrow_upward
+1.73%(+2.23) 1D
Nov 3, 9:42:51 AM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
$128.29
High
$131.32
Low
$128.26
Mkt. cap
14.89B
Avg. vol.
2.37M
Volume
25.64K
P/E ratio
39.20
52-wk high
$133.96
52-wk low
$61.22
EPS
$3.35
Beta
0.92
Shares outstanding
113.50M
No. of employees
423
Open
$128.29
High
$131.32
Low
$128.26
Mkt. cap
14.89B
Avg. vol.
2.37M
Volume
25.64K
P/E ratio
39.20
52-wk high
$133.96
52-wk low
$61.22
EPS
$3.35
Beta
0.92
Shares outstanding
113.50M
No. of employees
423
News stories
From web sources and news partners
Investing.com
·
33 minutes ago
MediWound’s EscharEx Strategy May Be Ahead of the Game as FDA Puts Chronic Wounds in Focus (Nasdaq: MDWD)
www.marketscreener.com
·
57 minutes ago
NYSE-Affiliated Venue for Tokenization Adds Transfer Agents: NYSE Content Update
Bloomberg
·
2 hours ago
UBS Traders See ‘Combustible Setup’ for S&P 500 Rally After Vote
Barchart.com
·
2 hours ago
Upstart (NASDAQ:UPST) posts better-than-expected sales in Q3 2026, stock soars
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com
Analyst ratings
Based on 7 analysts giving stock ratings to HALO in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for HALO in the last 3 months.
Highest
Current $131.18
$130.00 (-0.90%)
Average
$106.00 (-19.19%)
Lowest
$79.00 (-39.78%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Jessica Fye J.P. Morgan | Hold | Reiterated | $79.00 | -39.8% | 11/03/2026 |
Mitchell Kapoor H.C. Wainwright | Buy | Maintained | $130.00 | -0.9% | 11/02/2026 |
Brendan Smith TD Cowen | Buy | Reiterated | $130.00 | -0.9% | 10/13/2026 |
David Risinger Leerink Partners | Buy | Maintained | $110.00 | -16.1% | 10/07/2026 |
Sean Laaman Morgan Stanley | Buy | Reiterated | $105.00 | -20% | 08/07/2026 |
Jason Butler Citizens JMP | Buy | Maintained | $93.00 | -29.1% | 08/07/2026 |
Mohit Bansal Wells Fargo | Hold | Reiterated | $95.00 | -27.6% | 08/07/2026 |
Corinne Johnson Goldman Sachs | Sell | Maintained | $57.00 | -56.5% | 06/14/2026 |
Unknown Analyst J.P. Morgan | Hold | Maintained | $70.00 | -46.6% | 05/20/2026 |
Robert Wasserman Benchmark Co. | Buy | Maintained | $90.00 | -31.4% | 02/19/2026 |
Next call in 2 days
Thu, Nov 5, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.36
Revenue / Est. (USD)
- / 491.56M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 354.26M | 451.77M | 376.71M | 481.00M |
Cost of goods sold | 72.49M | 110.67M | 104.80M | 106.84M |
Cost of revenue | 72.49M | 110.67M | 104.80M | 106.84M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 46.09M | 63.33M | 57.88M | 57.00M |
Operating expense | 63.85M | 86.70M | 87.39M | 86.51M |
Total operating expenses | 136.34M | 197.37M | 192.19M | 193.34M |
Operating income | 217.92M | 254.40M | 184.52M | 287.65M |
Other non operating income | - | - | - | - |
EBT including unusual items | 218.96M | -100.85M | 180.33M | 284.90M |
EBT excluding unusual items | 218.96M | 251.58M | 180.30M | 284.90M |
Income tax expense | 43.73M | 40.74M | 30.28M | 54.99M |
Effective tax rate | 19.97% | -40.40% | 16.79% | 19.30% |
Other operating expenses | - | - | - | - |
Net income | 175.22M | -141.59M | 150.05M | 229.91M |
Net profit margin | 49.46% | -31.34% | 39.83% | 47.80% |
Earnings per share | 1.72 | -0.24 | 1.60 | 2.28 |
Interest and investment income | 5.33M | 2.09M | 1.29M | 2.84M |
Interest expense | -4.30M | -4.91M | -5.51M | -5.59M |
Net interest expenses | 1.04M | -2.82M | -4.22M | -2.75M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 236.84M | 279.08M | 215.65M | 319.12M |
Gain or loss from assets sale | - | 2.62M | - | 76.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events